Quadracel Vaccine Now Available in the US
In 2015, the CDC reported an 11% vaccination coverage drop-off from the third to fourth dose of DTaP.
Sanofi Pasteur has announced that the Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus; DTaP-IPV) vaccine has been made available. Quadracel was approved for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children aged 4 to 6 years old.
A single dose of Quadracel is approved as a fifth dose in the DTaP series and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel (DTap-IPV/Hib) and/or Daptacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).
In 2015, the Centers for Disease Control (CDC) reported an 11% vaccination coverage drop-off from the third to fourth dose of DTaP, and a 12% drop-off from the primary to full series of Haemophilus influenzae type b (Hib).
“When Quadracel is used in children who started their immunization series with Pentacel, it can save an extra shot and may help improve vaccination coverage for children through 6 years of age,” said David P. Greenberg, MD, associate vice president of Sanofi Pasteur.
Sanofi Pasteur announces the availability of Quadracel™ DTaP-IPV vaccine for children 4 through 6 years of age in the US [news release]. Swiftwater, PA: Sanofi Pasteur SA. Published January 31, 2017; Accessed February 2, 2017.